Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 26;64(3):2400347.
doi: 10.1183/13993003.00347-2024. Print 2024 Sep.

Association of airway inflammation and smoking status with IL-33 level in sputum of patients with asthma or COPD

Mustafa Abdo  1   2 , Frauke Pedersen  1   3   2 , Anne-Marie Kirsten  3 , Frederik Trinkmann  4   5 , Espen E Groth  1 , Thomas Bahmer  6 , Henrik Watz  3 , Klaus F Rabe  7
Affiliations

Association of airway inflammation and smoking status with IL-33 level in sputum of patients with asthma or COPD

Mustafa Abdo et al. Eur Respir J. .

Abstract

In patients with COPD, targeting IL-33 might be auspicious in former smokers. However, disease severity should also be considered. In patients with severe asthma, targeting IL-33 might be a potential treatment option, irrespective of T2-status. https://bit.ly/3SFspww

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: M. Abdo received travel support from Chiesi, and consulting fees from AstraZeneca, all outside the submitted work. F. Trinkmann reports grants from AstraZeneca, Bayer, Boehringer Ingelheim, Chiesi, Novartis, Roche, BMBF, DZL, Markedsmodningsfonden and E+H Knorr Stiftung, consultancy fees from AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Fisher & Paykel, GlaxoSmithKline, Janssen-Cilag, Merck Healthcare, Novartis, Omron, OM-Pharma, Roche, Sanofi-Aventis and Thorasys, payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Fisher & Paykel, GlaxoSmithKline, Janssen-Cilag, Merck Healthcare, Novartis, Omron, OM-Pharma, Roche, Sanofi-Aventis and Thorasys, and support for attending meetings from AstraZeneca, Actelion, Bayer, Berlin Chemie, Boehringer Ingelheim, Chiesi, Mundipharma, Novartis, Pfizer and TEVA. E.E. Groth reports grants from German Federal Ministry of Education and Research and Deutsche Forschungsgemeinschaft (DFG), payment or honoraria for lectures, presentations, manuscript writing or educational events from Dustri Verlag Germany, AstraZeneca, Germany, Health Course Inc., USA, Boehringer Ingelheim, Germany, Sanofi Genzyme, Germany and Insmed GmbH, Germany, and support for attending meetings from GlaxoSmithKline, Germany and Insmed, Germany. T. Bahmer reports grants from BMBF (unrestricted research grant for the German Center for Lung Research (DZL)), during the conduct of the study; consultancy fees from AstraZeneca and GlaxoSmithKline, payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca, GlaxoSmithKline, Novartis, Roche, Chiesi, Boehringer Ingelheim, Merck and Pfizer, support for attending meetings from Chiesi and AstraZeneca, and participation on a data safety monitoring board or advisory board with CoVit-2 (NCT04751604). H. Watz reports an unrestricted research grant from Chiesi, support from Bayer AG for the COPD cohort, consultancy fees from AZ, BI, Chiesi, GSK, Novartis and Sanofi, payment or honoraria for lectures, presentations, manuscript writing or educational events from AZ, BI, Chiesi, GSK, Novartis and Sanofi, support for attending meetings from AZ, BI, Chiesi, GSK, Novartis and Sanofi, and participation on a data safety monitoring board or advisory board with AZ, BI, Chiesi, GSK, Novartis and Sanofi. K.F. Rabe reports grants from Boehringer Ingelheim and AstraZeneca, payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals, Novartis, Sanofi & Regeneron, GlaxoSmithKline, Berlin Chemie and Roche Pharma, participation on a data safety monitoring board or advisory board with AstraZeneca, Boehringer Ingelheim, Sanofi & Regeneron and CSL Behring, and leadership roles with German Center for Lung Research (DZL), German Chest Society (DGP) and American Thoracic Society (ATS). The remaining authors have no potential conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
a) Boxplots illustrate sputum interleukin (IL)-33 protein levels in patients with COPD that were stratified based on disease severity grade and smoking status. Pre-COPD active smokers, n=9; pre-COPD ex-smokers, n=11; Global Initiative for Chronic Obstructive Lung Disease (GOLD) I/II active smokers, n=33; GOLD I/II ex-smokers, n=14; GOLD III/IV active smokers, n=7; GOLD III/IV ex-smokers, n=6. Number of patients with airway eosinophilia did not differ significantly between the COPD severity groups (p=0.26); pre-COPD, n=3; GOLD I/II, n=8; GOLD III/IV, n=5. ns: non-significant (p>0.05); *: p<0.05; **: p<0.01. b) Boxplots illustrate sputum IL-33 protein levels in patients with severe asthma who were classified according to the levels of type-2 inflammation markers. T2 high, n=25; T2 low, n=8.
See this image and copyright information in PMC

References

    1. Liew FY, Girard J-P, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol 2016; 16: 676–689. doi:10.1038/nri.2016.95 - DOI - PubMed
    1. Wechsler ME, Ruddy MK, Pavord ID, et al. . Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. N Engl J Med 2021; 385: 1656–1668. doi:10.1056/NEJMoa2024257 - DOI - PubMed
    1. Rabe KF, Celli BR, Wechsler ME, et al. . Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med 2021; 9: 1288–1298. doi:10.1016/S2213-2600(21)00167-3 - DOI - PubMed
    1. Yousuf AJ, Mohammed S, Carr L, et al. . Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. Lancet Respir Med 2022; 10: 469–477. doi:10.1016/S2213-2600(21)00556-7 - DOI - PubMed
    1. Faiz A, Mahbub RM, Boedijono FS, et al. . IL-33 expression is lower in current smokers at both transcriptomic and protein level. Am J Respir Crit Care Med 2023; 208: 1075–1087. doi:10.1164/rccm.202210-1881OC - DOI - PMC - PubMed